Morning Industry Symposium:
Recurrence risk and adjuvant treatment decision-making in HR+/HER2− early breast cancer
Supported by Novartis

 

Saturday, October 10, 2026 | Hall B (Great Hall 2)
07:30-08:30
Light refreshments will be served outside the hall from 07:00-07:30 for session participants only.
Admission to this symposium is included as part of the congress registration

Chairperson:
07:30-07:45 Opening Presentation
07:45-08:20 Case-Based Panel Discussion
08:20-08:30 Audience Q&A and Wrap-Up

 

Skip to content